April 27, 2026 —
Rejuvenate Bio, the gene therapy company co-founded by George Church, is taking an unconventional route to fund next-generation therapeutics—turning to crowdfunding to support development of its AAV gene therapy pipeline aimed at chronic diseases and the biology of aging.
Through the investment platform Wefunder, Rejuvenate is opening early-stage biotech investing to a broader community, allowing individual investors to participate in financing programs traditionally backed by venture capital. But beyond the novel financing model, the move is drawing attention because of the company’s ambitious scientific focus: using Adeno-associated virus (AAV) platforms to deliver one-time genetic medicines designed to treat age-related disease at its root.
Rejuvenate’s approach centers on reprogramming the body into a “living factory,” enabling durable therapeutic protein expression after a single administration. Unlike traditional gene replacement strategies targeting monogenic disorders, the company is applying AAV to broader chronic diseases, including metabolic, cardiac, and age-associated degeneration.
A key example is RJB-0402, Rejuvenate’s liver-targeting AAV gene therapy designed to drive sustained overexpression of FGF21, a hormone involved in metabolic regulation, inflammation, and tissue protection. Notably, the program is designed to work at doses meaningfully lower than those often required for conventional AAV replacement therapies, potentially improving scalability and safety.
The program has also shown promising preclinical results in arrhythmogenic cardiomyopathy (ACM), where a single dose of RJB-0402 improved cardiac function, preserved structural integrity, and reduced premature ventricular contractions to near-normal levels in animal models. These data underscore growing interest in using AAV not only for gene replacement, but increasingly for pathway modulation and disease reprogramming.
Rejuvenate has also generated attention for earlier animal studies suggesting gene therapy could reverse age-related cardiac disease and extend lifespan in dogs—results that support its broader thesis that aging-associated diseases may be addressable through durable genetic medicines.
An unusual part of the company’s strategy is its dual-market model, advancing therapies in animal health alongside human medicine. Rejuvenate believes veterinary programs can generate revenue and translational data that help de-risk and accelerate human clinical development, potentially offering a more capital-efficient route for advancing complex gene therapy programs.
The crowdfunding campaign itself reflects a growing willingness among biotech innovators to rethink financing models, especially for long-horizon technologies like genetic medicines and longevity therapeutics. For Rejuvenate, it is both a funding mechanism and a statement that participation in frontier biotech innovation can be broadened beyond traditional institutional circles.
As AAV platforms continue expanding beyond rare diseases into larger chronic indications, Rejuvenate’s strategy highlights an emerging frontier: using one-time gene therapies not simply to treat disease, but potentially to intervene in aging biology itself.
